News

PANTHERx Rare Pharmacy to Distribute Recorlev Therapy in US

Xeris Pharmaceuticals has selected the specialty pharmacy PANTHERx Rare to distribute Recorlev (levoketoconazole), the company’s therapy that was recently approved to treat adults with endogenous Cushing’s syndrome in whom surgery is not possible or not effective. “PANTHERx is proud to partner with Xeris to address the needs of adults…

Prepare to Light Up Buildings for Rare Disease Day 2022

The National Organization for Rare Disorders (NORD) asks Americans to plan ahead to participate in the Light Up for Rare campaign to raise awareness of rare diseases. NORD is the U.S. sponsor for Rare Disease Day on Feb. 28. The annual awareness day spotlights approximately 7,000…

Sparrow Cleared to Start Phase 2 Trial of SPI-62 Early Next Year

Sparrow Pharmaceuticals is gearing up for the start of a Phase 2 trial that will assess the safety and effectiveness of the company’s experimental medicine SPI-62 in people with Cushing’s disease. The U.S. Food and Drug Administration has cleared Sparrow’s investigational new drug application (IND), giving the company…

Study: Vitamin D Metabolism Altered in Cushing’s Patients

In people with Cushing’s disease, the activity of an enzyme that breaks down vitamin D is altered, which may affect the effectiveness of vitamin D dietary supplements, according to a new study. The study, “Assessment of Vitamin D Metabolism in Patients with Cushing’s Disease in Response…